Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Remschmidt, Cornelius ^a   Wichmann, Ole ^a   Harder, Thomas ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Diabetes; Effectiveness; Influenza; Meta analysis; Systematic review; Vaccine

Indexed keywords

INFLUENZA VACCINE;

AGE; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA VACCINATION; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PNEUMONIA; RISK ASSESSMENT; RISK FACTOR; SEASONAL INFLUENZA; SYSTEMATIC REVIEW; AGED; FEMALE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION;

EID: 84925374248     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0295-6     Document Type: Article

References (61)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
2. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
3. World Health Organization, Strategic Advisory Group of Experts (SAGE) Working Group. Background paper on influenza vaccines and immunization. 2012. http://www.who.int/entity/immunization/sage/meetings/2012/april/1_Background_Paper_Mar26_v13_cleaned.pdf?ua=1 . Accessed on 19 March, 2014.
4. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm Rep. 2013;62:1-43.
5. Public Health England: Chapter 19: Influenza. The green book. Updated 11 September 2013. https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19 . Accessed on 20 March 2014. 2013.
6. German Standing Committee on Vaccination (STIKO): [Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2013]. Epidemiologisches Bulletin 34/2013. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/34_13.pdf;jsessionid=7DE55B422304CC5842CE18900F8E43A1.2_cid372?__blob=publicationFile . Accessed on 19 March 2014. 2013.
7. National Advisory Committee on Immunization (NACI): Statement on seasonal influenza vaccine for 2013-2014. Canada communicable disease report. October 2013, Volume 39, ACS-4. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/index-eng.php . Accessed on 19 March, 2014. 2013.
8. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281-8.
9. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-3.
10. Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am. 2001;15:407-21.
11. Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010;65:870-7.
12. Collaboration ERF, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
13. Diepersloot RJ, Bouter KP, Beyer WE, Hoekstra JB, Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia. 1987;30:397-401.
14. Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38:1199-203.
15. Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine. 2013;31:3603-10.
16. Pozzilli P, Gale EA, Visalli N, Baroni M, Crovari P, Frighi V, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia. 1986;29:850-4.
17. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS. 1997;8:776-9.
18. El-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine. 1998;16:156-60.
19. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12:519-36.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9. W264.
21. Heymann AD, Shapiro Y, Chodick G, Shalev V, Kokia E, Kramer E, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care. 2004;27:2581-4.
22. Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, et al. Influenza vaccine effectiveness against hospitalisation and death in people with Type 2 diabetes. Wiley-Blackwell; 2014, p. 74-75. http://onlinelibrary.wiley.com/doi/10.1111/dme.12378_2/pdf .
23. Higgins J, Green S. Cochrane Handbook of Systematic Reviews of Interventions. Cochrane Collaboration. 2011. http://handbook.cochrane.org/ .
24. Guyatt GH, Oxman AD, Schunemann HJ. GRADE guidelines-an introduction to the 10th-13th articles in the series. J Clin Epidemiol. 2013;66:121-3.
25. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
26. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
27. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-2.
28. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66:173-83.
29. Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35:370-7.
30. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876.
31. Isotani H. Use of influenza vaccine in patients with diabetes, particularly those with complications of cardiac or renal disease. Intern Med. 2000;39:862.
32. Rodriguez-Blanco T, Vila-Corcoles A, de Diego C, Ochoa-Gondar O, Valdivieso E, Bobe F, et al. Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. Hum Vaccin Immunother. 2012;8:363-70.
33. Selvais PL, Hermans MP, Donckier JE, Buysschaert M. Reported rates, incentives, and effectiveness of major vaccinations in 501 attendees at two diabetes clinics. Diabetes Care. 1997;20:1212-3.
34. Schade CP, McCombs MA. Influenza immunization and mortality among diabetic Medicare beneficiaries in West Virginia. W V Med J. 2000;96:444-8.
35. Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax. 2013;68:658-63.
36. Colquhoun AJ, Nicholson KG, Botha JL, Raymond NT. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect. 1997;119:335-41.
37. Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V (R) and Fluad (R)) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Hum Vaccin Immunother. 2013;9:144-52.
38. Looijmans-Vanden Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006;29:1771-6.
39. Wang IK, Lin CL, Chang YC, Lin PC, Liang CC, Liu YL, et al. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine. 2013;31:718-24.
40. Dahlquist GG, Nystrom L, Patterson CC, Swedish Childhood Diabetes Study Group, Diabetes Incidence in Sweden Study Group. Incidence of type 1 diabetes in Sweden among individuals aged 0-34 years, 1983-2007: an analysis of time trends. Diabetes Care. 2011;34:1754-9.
41. Ehehalt S, Dietz K, Willasch AM, Neu A. Baden-Wurttemberg Diabetes Incidence Registry Group. Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany: 20 years of the Baden-Wurttemberg Diabetes Incidence Registry (DIARY). Diabetes Care. 2010;33:338-40.
42. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373:2027-33.
43. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-49.
44. Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269.
45. Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine. 2009;27:5357-62.
46. Vistoli F, Focosi D, De Donno M, Giannecchini S, Mariotti ML, Occhipinti M, et al. Pancreas rejection after pandemic influenza virus A(H1N1) vaccination or infection: a report of two cases. Transpl Int. 2011;24:e28-9.
47. Yasuda H, Nagata M, Moriyama H, Kobayashi H, Akisaki T, Ueda H, et al. Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report. Diabet Med. 2012;29:88-9.
48. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. 'I-MOVE' towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill. 2009;14:19388.
49. Navarro-Mari JM, Perez-Ruiz M, Cantudo-Munoz P, Petit-Gancedo C, Jimenez-Valera M, Rosa-Fraile M, et al. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol. 2005;58:275-9.
50. Woolpert T, Brodine S, Lemus H, Waalen J, Blair P, Faix D. Determination of clinical and demographic predictors of laboratory-confirmed influenza with subtype analysis. BMC Infect Dis. 2012;12:129.
51. Thomas RE. Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness? Vaccine. 2014;32:2143-9.
52. Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health. 2002;56:951-5.
53. Ridenhour BJ, Campitelli MA, Kwong JC, Rosella LC, Armstrong BG, Mangtani P, et al. Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged ≥65 years: estimates with generalized linear models accounting for healthy vaccinee effects. PLoS One. 2013;8:e76318.
54. Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, et al. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013;178:1327-36.
55. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35:337-44.
56. Beyer WE. Heterogeneity of case definitions used in vaccine effectiveness studies and its impact on meta-analysis. Vaccine. 2006;24:6602-4.
57. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-81.
58. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002;20:1831-6.
59. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658-66.
60. Nohynek H, Wichmann O, D Ancona F, VENICE National Gatekeepers. National Advisory Groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19:1096-105.
61. Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med. 2012;172:484-91.